1343 Efficacy of asymmetric siRNA targeting androgen receptor for the treatment of androgenetic alopecia

Comparison of the efficacy of valproic acid 8.3% and minoxidil 5% topical solutions in the treatment of androgenetic alopecia

Background and Aim: Hair loss is one of the most common problems among the skin and hair related diseases. Hair loss can lead to anxiety, depression, low self-esteem and dissatisfaction with appearance.   Methods: Patients with androgenetic alopecia who met the eligibility criteria entered the study. Participants were asked to randomly apply a solution of valproic acid 8.3% or a solution of...

Topical Melatonin for Treatment of Androgenetic Alopecia

BACKGROUND In the search for alternative agents to oral finasteride and topical minoxidil for the treatment of androgenetic alopecia (AGA), melatonin, a potent antioxidant and growth modulator, was identified as a promising candidate based on in vitro and in vivo studies. MATERIALS AND METHODS One pharmacodynamic study on topical application of melatonin and four clinical pre-post studies wer...

New Medical Treatment for Androgenetic Alopecia

Dihydrotestosterone(DHT) has played the pathogenic role in androgenetic alopecia. Patients with genetic deficiency of 5 alpha-reductase type II enzyme, which converts testosterone to DHT, do not have androgenic alopecia. The conversion of testosterone to DHT at hair follicles leads to miniaturization. In scalp biopsy, the tissue DHT level is significantly increased in balded area than non-balde...

Androgenetic alopecia and current methods of treatment.

Androgenetic alopecia (AGA) is a common dermatological condition affecting both men and women. In the case of men, up to 30% over the age of 30 and more than 50% over the age of 50 are affected. AGA also affects women although clinical signs are usually milder and associated with diffuse thinning of the scalp hair. AGA invariably causes serious psychological problems especially in women. By far...

Androgenetic Alopecia